Company news
Polyrizon Ltd. news in 2025
Polyrizon Ltd.'s news releases, calls and decks from 2025, newest first.
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
December 29, 2025
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
December 19, 2025
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
December 11, 2025
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
December 8, 2025
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
December 4, 2025
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
December 3, 2025
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
December 2, 2025
Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
November 6, 2025
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
October 6, 2025
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
September 19, 2025
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
September 12, 2025
Polyrizon Regains Compliance with Nasdaq Listing Requirements
August 14, 2025
Polyrizon Retains Nasdaq Listing Following Hearings Panel
July 15, 2025
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
June 12, 2025
Polyrizon Announces Receipt of Nasdaq Delisting Notice
May 23, 2025
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
May 21, 2025
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
May 13, 2025
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
April 25, 2025
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
April 11, 2025
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
April 2, 2025
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
April 1, 2025
Polyrizon Ltd. Announces $17.0 Million Private Placement
March 31, 2025
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
March 27, 2025
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
March 25, 2025
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
March 14, 2025
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
March 13, 2025
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
March 11, 2025
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
March 10, 2025
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
January 29, 2025
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
January 22, 2025